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Metzincins, a family of zinc metalloproteinases able to process all the extracellular matrix 
(ECM) components, include the matrix metalloprotease (MMP), a disintegrin and 
metalloproteinase (ADAM), and a disintegrin and metalloproteinase with thrombospondin 
motifs (ADAMTS) subfamilies. Metzincins are important regulators of tissue remodeling, 
particularly vascular remodeling during atherosclerosis development.1 In the 
atherosclerotic artery wall these enzymes cause profound alterations to the ECM, and 
these alterations instigate changes in the behavior of endothelial cells (ECs) and vascular 
smooth muscle cells (VSMCs).2 Recent genome-wide association (GWA) studies have 
identified ADAMTS7 as a novel locus associated with human coronary atherosclerosis.3, 4  
However, a causal link between this secreted zinc metalloprotease and atherosclerosis 
has yet to be established. In this issue of Circulation, Bauer and colleagues5 directly 
address this hypothesis by generating whole-body knock-out mice for Adamts7 for the 
investigation of atherosclerosis development. The authors crossed Adamts7-null mice with 
the atherosusceptible apoE-KO and Ldlr-KO mouse models and found that deletion of 
Adamts7 significantly reduced atherosclerotic lesion formation in the aortas and aortic 
roots of both hyperlipidemic strains. The atheroprotective effect of Adamts7 deletion 
occurred without significant changes in plasma lipid levels or plaque composition, and was 
associated with impeded migration of Adamts7-null VSMCs in response to TNF. The 
early and transient upregulation of Adamts7 in the plaques of atheroprone mice suggests 
that Adamts7 makes an important contribution at early stages of the disease. However, 
mouse models are of limited use for the analysis of late atherosclerotic and thrombotic 
events, and ADAMTS7 is expressed at all stages in human plaques. Therefore further 
analysis is clearly required in order to understand the significance of these observations. 
Consistent with the association of ADAMTS7 with atherosclerosis but not with myocardial 
infarction, Bauer et al5 detected a tendency of plaques in Adamts7-null mice to develop a 
larger fibrous cap, a finding that should be fully explored to determine whether targeting 
ADAMTS7 in patients might result not only in decreased atherosclerosis but also in more 
stable plaques. Studies are also needed to investigate whether atherosclerosis-associated 
ADAMTS7 genetic variants associate with restenosis or arterial calcification, as recently 
suggested.6  Overall, the studies presented by Bauer at al5 provide the first firm evidence 
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that mouse Adamts7 plays a proatherogenic role, likely through the promotion of VSMC 
migration.  
The long-term success of percutaneous coronary intervention is limited by restenosis, a 
pathological process characterized by excessive neointimal thickening caused by the 
inflammatory response associated with mechanical injury to the vessel wall.7 Like native 
atherosclerosis, restenosis involves activation of zinc metalloproteinases that alter the 
ECM.2 The studies by Bauer and colleagues5 and Kessler and colleagues8 (a second 
study also published in this issue of Circulation) both report that genetic deletion of 
Adamts7 reduces neointimal thickening after wire injury to the femoral and carotid arteries. 
These results are consistent with previous studies showing that Adamts7 increases 
neointima formation in balloon-injured rat arteries by stimulating VSMC migration through 
the degradation of cartilage oligomeric matrix protein (COMP, also called thrombospondin-
5).9  Kessler and colleagues8 shed further light on the role of Adamts7 in vascular 
remodeling by focusing on vessel re-endothelialization, which is inversely related to 
neointima formation. They found that Adamts7 inhibits EC proliferation and migration in 
vitro and that reendothelialization is strongly augmented in the injured vessels in Adamts7-
null mice.8 Surprisingly, COMP expression did not affect EC proliferation/migration in vitro, 
and Comp deficiency had no effect on reendothelialization in injured arteries, suggesting 
that Adamts7 retards endothelium repair via COMP-independent mechanisms.8 Using 
label-free LC MS/MS secretome analysis, coimmunoprecipitation strategies and 
mammalian two-hybrid analysis, Kessler and coworkers8 found that Adamts7 can bind 
directly to thrombospondin-1 (TSP-1) and degrade it in vitro. In agreement with earlier 
mouse studies showing the beneficial effects of TSP-1 inactivation on reendothelialization 
and neointima formation,10 the inhibitory effect of Adamts7 overexpression on EC 
proliferation and migration was blunted in Tsp-1 silenced endothelial cells in vitro, and 
Adamts7-dependent inhibition of reendothelialization was circumvented in Tsp-1-null 
mice.8 The study by Kessler et al8 thus suggests that ADAMTS7 exerts complementary 
functions in neointima formation by selective and cell-type-dependent substrate 
processing: COMP cleavage  mediating augmented VSMC migration whereas TSP-1 
degradation mediates impaired EC recovery (Figure 1). However, the in vivo relevance of 
Adamts7-mediated processing in EC responses during neointima formation remains 
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undefined. EC-specific Adamts7 deletion in conditional mouse models will help to confirm 
the EC-selective function of Adamts7 and reconcile the data about its expression and 
function in ECs in vivo (see below).  
Both Adamts7-null mouse strains have a LacZ reporter gene in the gene-trapping 
cassette, allowing for X-gal staining as readout of active Adamts7 expression, which was 
detected in heart tissue and pulmonary vasculature.5, 8 This  staining allowed analysis of 
the dynamics of Adamts7 expression in SM--actin-immunoreactive cells in response to 
mechanical vascular injury and hyperlipidemia, revealing an early, transient upregulation,5 
consistent with the action of ADAMTS7 as a positive regulator of neointimal thickening. 
Notably, previous in vitro findings showed upregulation of ADAMTS7 expression in VSMCs 
by inflammatory cytokines (TNFα, IL-1, PDGFB), but not by anti-inflammatory cytokines 
(TGFB) or oxidized LDL.4 This would suggest that ADAMTS7 responds to inflammation 
rather than to hyperlipidemia, in line with the recognized role of ADAMTS7 in arthritis.4 The 
study by Bauer et al5 also provides insight into the cell distribution of Adamts7, which is 
mainly detected in the media and adventitia of mouse aortas but not in ECs. Further 
expression studies are needed to clarify the spatial and temporal pattern of ADAMTS7 
expression in the cell types of the injured vessel wall—including direct 
immunohistochemical detection of Adamts7 in rodent arteries using specific antibodies and 
quantification of expression levels (e.g. real-time PCR, western blot). In contrast to the 
Adamts7 expression pattern in the media and adventitia of mouse arteries, 
immunohistochemistry analysis in human coronary and carotid arteries revealed 
ADAMTS7 expression in only a proportion of VSMCs in atherosclerotic plaques, 
predominantly near the media-intima border and the fibrous cap.5, 11 The absence of 
ADAMTS7 staining in CD68-labeled macrophages indicates the need for further work to 
expand the repertoire of molecular markers for selective cell subsets, in order to better 
define the populations expressing ADAMTS7 in the intima of human atherosclerotic 
plaques. It will be also important to analyze ADAMTS7 expression in human 
atherosclerotic and restenotic lesions at different stages of disease progression.   
The study by Bauer et al5 positions ADAMTS7 in primary aortic VSMCs in specialized 
membrane protrusions called podosomes, which are actively involved in matrix 
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degradation and cell invasiveness. In this location, ADAMTS7 might associate with 
adhesion receptors such as integrins or other proteases to exert coordinated functions in 
vascular remodeling.12 Given the emerging idea that podosomes can sense matrix 
stiffness,13 it is appealing to propose that ADAMTS7 modulates matrix tension in the 
vessel wall by processing COMP near podosomes to interfere with its binding to α7β1 
integrin—a recognized mechanosensor at myotendinous junctions14—which could 
ultimately lead to pathologic vascular remodeling.15  
ADAMTS7 posseses mucin-proteoglycan domains, and interacts with COMP through its 
four C-terminal TSP repeats.4 Additional structural studies of the ADAMTS7/COMP 
complex will shed light on the potential value of targeting the ADAMTS7 catalytic site or 
selective exosite binding motifs to avoid adverse effects on related proteases such as 
ADAMTS12, which is also able to process COMP.16  The identification by Kessler et al8 of 
the matricellular protein TSP-1 as a novel ADAMTS7 substrate in ECs is important, but the 
selectivity of this processing and its role in vascular remodeling is as yet unclear since 
TSP1 can be cleaved by other metalloproteases, including  ADAMTS1, ADAMTS13 and 
MT1-MMP.17  It will also be important to identify the ADAMTS7 clevage sites in COMP and 
TSP-1 and define whether they are unique or shared with other metalloproteases, and 
whether cleavage can generate bioactive polypeptide fragments able to bind cell receptors 
that trigger EC and VSMC responses. The identification of specific ADAMTS7 cleavage 
sites would also permit direct in vivo investigation of the relevance of COMP and TSP-1 
processing to atherosclerosis by generating cleavage-resistant knock-in mice, as 
previously achieved for collagen I processing.18  Since ADAMTS7 is thought to be a 
nonredundant member of the ADAMTS family,4 the search for other unique ADAMTS7 
substrates and interacting proteins in the artery wall might also provide new opportunities 
for therapeutic intervention. 
The studies by Bauer and colleagues5 and Kessler and colleagues8 conclusively 
demonstrate a pro-atherogenic role for mouse Adamts7. A key outstanding question is 
whether any of these laboratory findings in mouse models can be translated back to the 
clinic (Figure 2). Recent studies have begun to assess whether human ADAMTS7 alleles 
associated with high risk of coronary atherosclerosis are linked to higher ADAMTS7 
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expression or activity in tissues and cells involved in disease development. For example, 
the rs3825807 G/G genotype in the ADAMTS7 locus, which is associated with lower 
atherosclerosis prevalence and severity, reduces not the expression of ADAMTS7 but its 
maturation and activity, resulting in reduced COMP cleavage and attenuated VSMC 
migration.11 It will be of interest to assess whether the rs3825807 G/G genotype also 
affects TSP-1 degradation in ECs. Further research in this area could lead to personalized 
medicine based on the identification of ADAMTS7 genetic variants in patients with 
atherosclerosis who could benefit from strategies targeting this proteolytic pathway. 
Quantification of COMP or TSP-1 fragments in plasma of these patients might also provide 
valuable information about the severity or progression of atherosclerotic disease, as 
shown for COMP in arthritis.19  Despite the lack of success with inhibitors of the closely 
related MMP subfamily, the strong GWAS association of ADAMTS7 with atherosclerosis, 
together with the solid knowledge being generated about the mechanisms of action of 
ADAMTS7-mediated vascular remodeling, may pave the way for the development of novel 
strategies to ameliorate atherosclerosis and restenosis. These therapeutic approaches 
might include targeting ADAMTS7 catalytic or C-terminal exosites, locking the ADAMTS7 
propetide-catalytic domain conformation (as in the G/G rs3825807 variant), delivering 
substrates to restore homeostasis (e.g. via viral-based approaches), inhibiting signaling 
pathways triggered by ADAMTS7 substrate fragments, or decreasing ADAMTS7 
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Figure 1. ADAMTS7-mediated actions on vascular smooth muscle cells and 
endothelial cells promote neointima formation. ADAMTS7 expression is upregulated in 
vascular smooth muscle cells (VSMCs) upon vascular injury, leading to processing of the 
α7β1 integrin ligand COMP (cartilage oligomeric matrix protein) and increased VSMC 
migration. Complementary actions of ADAMTS7 have been proposed in endothelial cells 
(ECs) via cleavage of thrombospondin-1 (TSP-1), resulting in bioactive TSP-1 fragments 
that would reduce EC migration and proliferation and thus impair EC recovery. However, 
more evidence is needed about ADAMTS7 expression and actions on ECs in vivo. The 
combined effect of Adamts7-mediated increased VSMC migration and impaired re-
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Figure 2. Proposed translation of research on ADAMTS7 in atherosclerosis and 
cardiovascular disease from bedside to bench and back again. Clinical and basic 
research on ADAMTS7 in cardiovascular disease (CVD) exemplifies successful 
translational research. The identification of ADAMTS7 variants associated with 
atherosclerosis (AT) by GWAS in patients prompted basic researchers to generate loss-of-
function mouse models to directly test the pathogenic role of ADAMTS7 in atherosclerosis. 
Two independent studies in this issue of Circulation show that Adamts7 deletion protects 
mice from atherosclerosis and restenosis.5, 8 Potential applications of Adamts7-related 
laboratory findings in the clinic include genetic analysis of CVD risk, use of ADAMTS7 
substrates as biomarkers for AT progression, and personalized medicine in selected 
patients with pathogenic ADAMTS7 variants.  
 
 
 
 
